Efficacy of using Synbiotics during neoadjuvant chemotherapy in pancreatic and biliary cancer patients

Efficacy of using Synbiotics during neoadjuvant chemotherapy in pancreatic and biliary cancer patients - Synbiotics during neoadjuvant chemotherapy in pancreatic and biliary cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008150

Enrollment

Registered

2012-06-12

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer, biliary cancer

Interventions

Synbiotics treatment during chamoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pancreatic and biliary cancer, who are scheduled to receive neoadjuvant chemoradiotherapy -Performance status is 0-2 -No serious abnormality in heart, lung, bone marrow, liver, and renal functions

Exclusion criteria

Exclusion criteria: patients who reject to be enrolled in this study Patients who are judged inappropriate for the entry into the study by the investigater

Design outcomes

Primary

Measure	Time frame
Nutritional parameter	—

Secondary

Measure	Time frame
Incidence of adverse events during chemoradiotherapy, Incidence of postoperative infectious complications, fecal microflora, fecal organic acid	—

Countries

Japan

Contacts

Public ContactKunihito Gotoh

Osaka Medical Center for Cancer and Cardiovascular Diseases Surgery

gotou-ku@mc.pref.osaka.jp06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026